ethylisopropylamiloride and s 1743

ethylisopropylamiloride has been researched along with s 1743 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Balza, E; Carlone, S; Carta, S; Castellani, P; Cossu, V; Marini, C; Piccioli, P; Rubartelli, A; Sambuceti, G	1

Other Studies

1 other study(ies) available for ethylisopropylamiloride and s 1743

Article	Year
Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. Cancer medicine, 2022, Volume: 11, Issue:1 Topics: Amiloride; Animals; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Cisplatin; Esomeprazole; Female; Humans; Hydrogen-Ion Concentration; Mice, Inbred BALB C; Proton Pump Inhibitors; Sodium-Hydrogen Exchanger 1; Triple Negative Breast Neoplasms; Tumor-Associated Macrophages; Vacuolar Proton-Translocating ATPases	2022

Article

Year

Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models.

Cancer medicine, 2022, Volume: 11, Issue:1

Topics: Amiloride; Animals; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Cisplatin; Esomeprazole; Female; Humans; Hydrogen-Ion Concentration; Mice, Inbred BALB C; Proton Pump Inhibitors; Sodium-Hydrogen Exchanger 1; Triple Negative Breast Neoplasms; Tumor-Associated Macrophages; Vacuolar Proton-Translocating ATPases

2022